CELLNEX: 2Q’20 RESULTS (ANÃLISIS BANCO SABADELL)
2Q'20 vs 2Q'19 Results
Sales: € 365.0 M (+47.2% vs. +46.4% BS(e) and +46.8% consensus);
EBITDA: € 267.0 M (+64.8% vs. +64.2% BS(e) and +63.6% consensus);
Net Profit: € -13.0 M.
1H'20 vs 1H'19 Results
Sales: € 723.0 M (+47.9% vs. +47.4% BS(e) and +47.6% consensus);
EBITDA: € 527.0 M (+64.2% vs. +63.9% BS(e) and +63.6% consensus);
EBIT: € 70.0 M;
Net Profit: € -43.0 M (vs. € 0 M 1H’19).
The results were in line with expectations, with EBITDA growing by +64.8% in 2Q’20 and RLFCF (Recurrent Levered FCF) totalling € 267 M in the 1H’20 (+54% and +6.9% organic vs. 1H’19), which shows the robustness of the business and its high visibility, maintaining the growth rates registered before Covid-19. 2Q’20 sales came in at € 365 M (+47% vs. 46.2% BS(e)), boosted by towers sales (+70% vs. +69% BS(e)) due to the effect from the scope of consolidation and organic growth (+5% in PoPs). 1H’20 Net Profit came in at €-43 M due to a higher level of amortisations (€ 423 M in the 1H’20 vs. € 217 M in the 1H’19), non-recurring costs (€-34 M in the 1H’20 vs. €-15 M in the 1H’19) and higher financial costs (€ 135 M in the 1H’20 vs. €-110 M in the 1H’19).
To include the impact from Arqiva (~5.5 months) and NOS (~3 months), the company has raised its guidance’20 to € 1.16-€-1.18 Bn (around +70% vs. € 1.06-€1.08 Bn previously and vs. € 1.11 Bn BS(e)). Likewise, it expects RLFCF to increase by >70% (vs. >50% previously and vs. +57.5% BS(e)). We recall that our estimates include 2.2 months of Arqiva and 3 months of NOS. If we included 5.5 months of Arqiva, our EBITDA estimate would be € 1.16 Bn (in the low range of the guidance) and RLFCF would increase by +69%.
We do not expect a significant market impact from these positive results (as expected) following the stock’s recent good performance (+49% in absolute terms in 2020 and +70.7% vs. Ibex). The key will lie in the messages that the company may provide in the conference call (22 Jul at 18:30 (CET)) on the pipeline of inorganic operations (the company will provide news shortly) and the possibility of executing a rights issue, as rumoured by the press. We recall that our base-case scenario includes a €~4.6 Bn rights issue (~22% of the market cap), which would give the company financial muscle to carry out transactions totalling € 13 Bn while maintaining its NFD/EBITDA ratio at ~6x.